Eva Anette Engelhardt - 04 Sep 2026 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Reporting relationship: EVP, President, CDG
Issuer ticker: BIO
Reported as of: 04 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Sep 2026, 18:45:58 UTC
Prior SEC filing: 28 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Eva Anette Engelhardt

Filing notes and source

Key filing fact

Eva Anette Engelhardt filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 09 Sep 2026.

Key facts

This page summarizes Eva Anette Engelhardt's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 09 Sep 2026, 18:45.

Change

Previous filing in this sequence was filed on 28 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002024911 Primary reporting owner

ENGELHARDT EVA ANETTE

Relationship: EVP, President, CDG
Address: C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES
Signature: /s/ Eva Anette Engelhardt
Signature date: 09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value
Shares: +1,027
Change %: +204%
Price: $0.000000^*
Shares after: 1,530
Date: 05 Sep 2026
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value
Shares: -369
Change %: -24%
Price: $386.11^*
Shares after: 1,161
Date: 05 Sep 2026
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value
Shares: +1,152
Change %: +99%
Price: $0.000000^*
Shares after: 2,313
Date: 06 Sep 2026
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value
Shares: -485
Change %: -21%
Price: $386.11^*
Shares after: 1,828
Date: 06 Sep 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIO transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +4,313
Change %
Price: $0.000000^*
Shares after: 4,313
Date: 04 Sep 2026
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 4,313
Exercise price: $0.000000
Footnotes: F2, F3

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -1,027
Change %: -25%
Price: $0.000000^*
Shares after: 3,083
Date: 05 Sep 2026
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 1,027
Exercise price: $0.000000
Footnotes: F2, F4

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -1,152
Change %: -33%
Price: $0.000000^*
Shares after: 2,304
Date: 06 Sep 2026
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 1,152
Exercise price: $0.000000
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Shares of Class A common stock acquired on the vesting of restricted stock units.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

Footnote F3

The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.

Footnote F4

The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.